ArticleEuropean radiology2026
Recurrence patterns and survival outcomes after irreversible electroporation for hepatocellular carcinoma: a 6-year multicenter experience.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Irreversible electroporation vs. stereotactic body radiotherapy for solitary hepatocellular carcinoma ≤5 cm: A multicenter retrospective study.JHEP reports : innovation in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesIrreversible electroporation (IRE) is a relatively recent non-thermal ablation technique for hepatocellular carcinoma (HCC) in high-risk anatomical locations, but post-procedural recurrence limits long-term survival. This study aimed to investigate the risk factors, patterns, and outcomes of post-IRE recurrence. MATERIALS AND
methodsThis study retrospectively analyzed 180 patients with solitary HCC (≤ 5 cm) who underwent IRE at five centers. Recurrence was categorized as local tumor progression (LTP), intrahepatic distant recurrence (IDR), aggressive intrasegmental recurrence (AIR), and extrahepatic distant recurrence (EDR). Competing-risk regression models and dynamic risk curves were utilized to assess risk factors and temporal trends.
resultsOver a mean follow-up of 40.9 ± 12.6 months, 50.6% of patients developed recurrence. IDR was the predominant pattern (41.7%), followed by LTP (10.0%), EDR (8.3%), and AIR (1.7%). Multivariate analysis identified cirrhosis and tumor size as predictors of LTP; recurrent HCC and cirrhosis as predictors of IDR; and the male sex, cirrhosis, and tumor size as predictors of EDR (all p < 0.05). Only EDR was an independent risk factor for worse overall survival (p < 0.001). Recurrence risk demonstrated a bimodal pattern, with peaks at 21 and 33 months.
conclusionIDR is the dominant post-IRE recurrence pattern, but only EDR predicts survival. The identified risk factors and bimodal recurrence peaks contribute to guiding stratified therapeutic strategies for HCC in high-risk locations. KEY POINTS: Question Current knowledge of post-ablation recurrence patterns for hepatocellular carcinoma is primarily derived from thermal ablation, lacking data for non-thermal irreversible electroporation. Findings Intrahepatic distant recurrence was the most common recurrence pattern, while only extrahepatic distant recurrence predicted worse survival. Clinical relevance Irreversible electroporation provided excellent local control for high-risk hepatocellular carcinoma but struggled with recurrence. While extrahepatic distant recurrence predicted reduced survival, local or intrahepatic recurrences yielded favorable outcomes with salvage therapy.
Indexed as
Identifiers
41042373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.